SEARCH:   Advanced

Blood, 15 June 2006, Vol. 107, No. 12, pp. 4954-4960. Prepublished online as a Blood First Edition Paper on February 23, 2006; DOI 10.1182/blood-2005-09-3883. This Article Full Text Full Text (PDF) All Versions of this Article: 2005-09-3883v1 107/12/4954    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Slager, E. H. Articles by Falkenburg, J. H. F. Search for Related Content PubMed PubMed Citation Articles by Slager, E. H. Articles by Falkenburg, J. H. F. Related Collections Hemostasis, Thrombosis, and Vascular Biology Neoplasia Transplantation Immunotherapy Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  TRANSPLANTATION Identification of the angiogenic endothelial-cell growth factor-1/thymidine phosphorylase as a potential target for immunotherapy of cancer Elisabeth H. Slager, M. Willy Honders, Edith D. van der Meijden, Simone A. P. van Luxemburg-Heijs, Freke M. Kloosterboer, Michel G. D. Kester, Inge Jedema, W. A. Erik Marijt, M. Ron Schaafsma, Roel Willemze, and J. H. Frederik Falkenburg From the Laboratory of Experimental Hematology, Department of Hematology, Leiden University Medical Center, Leiden, The Netherlands; and the Department of Hematology, Medisch Spectrum Twente, Enschede, The Netherlands. Characterization of the antigens recognized by tumor-reactive T cells isolated from patients successfully treated with allogeneic HLA-matched hematopoietic stem cell transplantation (SCT) can lead to the identification of clinically relevant target molecules. We isolated tumor-reactive cytotoxic CD8+ T-cell (CTL) clones from a patient successfully treated with donor lymphocyte infusion for relapsed multiple myeloma after allogeneic HLA-matched SCT. Using cDNA expression cloning, the target molecule of an HLA-B7–restricted CTL clone was identified. The CTL clone recognized a minor histocompatibility antigen produced by a single nucleotide polymorphism (SNP) in the angiogenic endothelial-cell growth factor-1 (ECGF1) gene also known as thymidine phosphorylase. The SNP leads to an Arg-to-His substitution in an alternatively translated peptide that is recognized by the CTL. The ECGF1 gene is predominantly expressed in hematopoietic cells, although low expression can also be detected in other tissues. The patient from whom this CTL clone was isolated had mild graft-versus-host disease despite high numbers of circulating ECGF-1–specific T cells as detected by tetramer staining. Because solid tumors expressing ECGF-1 could also be lysed by the CTL, ECGF-1 is an interesting target for immunotherapy of both hematologic and solid tumors. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: A. N. Stumpf, E. D. van der Meijden, C. A. M. van Bergen, R. Willemze, J. H. F. Falkenburg, and M. Griffioen Identification of 4 new HLA-DR-restricted minor histocompatibility antigens as hematopoietic targets in antitumor immunity Blood, October 22, 2009; 114(17): 3684 - 3692. [Abstract] [Full Text] [PDF] W. J. Norde, I. M. Overes, F. Maas, H. Fredrix, J. C. M. Vos, M. G. D. Kester, R. van der Voort, I. Jedema, J. H. F. Falkenburg, A. V. Schattenberg, et al. Myeloid leukemic progenitor cells can be specifically targeted by minor histocompatibility antigen LRH-1-reactive cytotoxic T cells Blood, March 5, 2009; 113(10): 2312 - 2323. [Abstract] [Full Text] [PDF] M. Griffioen, H.M. E. van Egmond, H. Barnby-Porritt, M. A.W.G. van der Hoorn, R. S. Hagedoorn, M. G.D. Kester, N. Schwabe, R. Willemze, J.H. F. Falkenburg, and M. H.M. Heemskerk Genetic engineering of virus-specific T cells with T-cell receptors recognizing minor histocompatibility antigens for clinical application Haematologica, October 1, 2008; 93(10): 1535 - 1543. [Abstract] [Full Text] [PDF] M. Griffioen, E. D. van der Meijden, E. H. Slager, M. W. Honders, C. E. Rutten, S. A. P. van Luxemburg-Heijs, P. A. von dem Borne, J. J. van Rood, R. Willemze, and J. H. F. Falkenburg Identification of phosphatidylinositol 4-kinase type II {beta} as HLA class II-restricted target in graft versus leukemia reactivity PNAS, March 11, 2008; 105(10): 3837 - 3842. [Abstract] [Full Text] [PDF] T. Kawase, Y. Akatsuka, H. Torikai, S. Morishima, A. Oka, A. Tsujimura, M. Miyazaki, K. Tsujimura, K. Miyamura, S. Ogawa, et al. Alternative splicing due to an intronic SNP in HMSD generates a novel minor histocompatibility antigen Blood, August 1, 2007; 110(3): 1055 - 1063. [Abstract] [Full Text] [PDF] C. A. M. van Bergen, M. G. D. Kester, I. Jedema, M. H. M. Heemskerk, S. A. P. van Luxemburg-Heijs, F. M. Kloosterboer, W. A. E. Marijt, A. H. de Ru, M. R. Schaafsma, R. Willemze, et al. Multiple myeloma-reactive T cells recognize an activation-induced minor histocompatibility antigen encoded by the ATP-dependent interferon-responsive (ADIR) gene Blood, May 1, 2007; 109(9): 4089 - 4096. [Abstract] [Full Text] [PDF] A. Mullally and J. Ritz Beyond HLA: the significance of genomic variation for allogeneic hematopoietic stem cell transplantation Blood, February 15, 2007; 109(4): 1355 - 1362. [Abstract] [Full Text] [PDF]

	Copyright © 2006 by American Society of Hematology         Online ISSN: 1528-0020